<DOC>
	<DOCNO>NCT00715247</DOCNO>
	<brief_summary>The purpose project find gene whose mutation cause Polycythemia Vera , Essential Thrombocythemia Primary Myelofibrosis .</brief_summary>
	<brief_title>Polycythemia Vera , Myelofibrosis Essential Thrombocythemia : Identification PV , MF &amp; ET Genes</brief_title>
	<detailed_description>Polycythemia Vera ( PV ) , Essential Thrombocythemia ( ET ) Primary Myelofibrosis ( PMF ) , also know Philadelphia Chromosome negative myeloproliferative disorder ( MPDs ) , congenital , acquire . The purpose project find gene whose mutation cause disorder , well improve diagnostic measure disease . When accomplished new therapy control eventually cure disease design . All subject ask donate 4-6 teaspoon blood . On occasion , blood cell particular sample grow well DNA sample use test need , may ask collect additional sample . In patient undergone bone marrow biopsy part clinical evaluation , test reproducibility pathologist revise 2008 WHO diagnostic criterion diagnose myeloproliferative disorder ( MPD ) .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>1 . Patients elevate hemoglobin concentration ( &gt; 18 male &gt; 16 female ) suspect congenital acquire primary polycythemia 2 . Patients persistent thrombocytosis ( &gt; 400,000 ) obvious secondary cause 3 . Patients bone marrow biopsy show increase cellularity fibrosis 4 . Patients clinical concern primary myelofibrosis , anemia combination leukocytosis , thrombocytosis , splenomegaly and/or leukoerythroblastic blood smear 5 . Patients thrombosis unusual site , BuddChiari syndrome , early PV hemoglobin elevate , patient also include . 1 . Subjects know acquire cause polycythemia ( increased hemoglobin/hematocrit ) people live high altitude ( excess 14,000 foot ) , subject heart disease , leave right heart shunt , severe hypoxia severe pulmonary disease exclude study . 2 . Subjects know acquire cause thrombocytosis . 3 . Subjects exclude demonstrate decision make capacity sufficient agree decline blood draw use blood study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Myeloproliferative Disorders</keyword>
	<keyword>Hematological Malignancies</keyword>
	<keyword>Polycythemia Vera</keyword>
	<keyword>Essential Thrombocythemia</keyword>
	<keyword>Myelofibrosis</keyword>
	<keyword>Genetics</keyword>
	<keyword>Chronic Leukemia</keyword>
</DOC>